Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Plasma Anti-Mullerian Hormone in Breast Cancer

Cancer Epidemiol Biomarkers Prev; ePub 2016 Mar 9; Eliassen, et al

Publish date:: March 28, 2016

Higher circulating anti-Müllerian hormone (AMH) levels are associated with increased breast cancer risk among premenopausal women, according to a study of blood samples from 62,437 women, including 539 who were later diagnosed with breast cancer and 539 matched controls. Researchers found:

• Higher plasma levels of AMH were associated with increased breast cancer risk (top vs bottom quintile OR=2.20).

• This association did not vary by invasive vs in situ disease or by estrogen receptor status.

• Associations were not significantly different by age at blood sampling or at diagnosis.

• Additional adjustment for plasma estradiol or testosterone yielded similar results.

Citation: Eliassen AH, Zeleniuch-Jacquotte A, Rosner B, Hankinson SE. Plasma anti-Müllerian hormone concentrations and risk of breast cancer among premenopausal women in the Nurses' Health Studies. [Published online ahead of print March 9, 2016]. Cancer Epidemiol Biomarkers Prev. doi:10.1158/1055-9965.EPI-15-1240.

This Week's Must Reads

Higher dose maximizes effects of magnesium sulfate for obese women,

‘Impressive’ local control with MRI-guided brachytherapy in cervical cancer,

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Microplastics permeate human placentas,

One in five gestational carriers do not meet ASRM criteria,

Must Reads in Breast Cancer

U.S. mothers underestimate role breastfeeding plays in curbing breast cancer,

Long-term APBI cosmetic, toxicity data reported WBI has the edge Practice-confirming results,

Pregnancy after breast cancer is rockier but doesn't increase recurrence risk,

Breast surgery may be a gateway to addictive medication use,

Immune checkpoint inhibitors don’t increase COVID-19 incidence or mortality, studies suggest,